Pyxis Oncology retains rights to three additional antibodies in development that were also discovered through the APXiMAB platform. President and CEO of Pyxis Oncology, Lara S. Sullivan, M.D., stated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback